In our 2021 U.S. Transparency Report, we highlighted a continued decline in net prices for our medications, marking the fifth consecutive year of such reductions. The report also emphasized our substantial investment in research and development, aiming to advance innovative treatments for patients.
View the full report here.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.